Literature DB >> 11350782

Systemic and regional free fatty acid metabolism in type 2 diabetes.

A Basu1, R Basu, P Shah, A Vella, R A Rizza, M D Jensen.   

Abstract

To determine whether type 2 diabetes mellitus alters systemic and regional free fatty acid ([3H]palmitate) metabolism, 14 nondiabetic (ND) and 14 type 2 diabetic (D) subjects underwent hyperinsulinemic-hyperglycemic (approximately 9.3 mM) clamps. The subjects were matched for age, body mass index, percent body fat, and fat-free mass. D subjects had more (P < 0.05) visceral fat than ND. During somatostatin, replacement growth hormone, and glucagon infusions, insulin was infused to achieve moderate (approximately 75 pmol/l) and high (approximately 150 pmol/l) physiological insulin levels. D subjects had greater (P < 0.02) systemic and regional (splanchnic and leg) palmitate release than ND subjects during both insulin infusion intervals. The relative contributions of splanchnic, leg, and nonsplanchnic upper body regions to systemic palmitate release did not differ between groups, although the last contributed the most (approximately 75%) to systemic palmitate release. Visceral fat area correlated with systemic palmitate flux (r = 0.45, P < 0.03) during both insulin infusions. We conclude that type 2 diabetes is associated with a generalized impairment in insulin suppression of lipolysis compared with equally obese ND individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350782     DOI: 10.1152/ajpendo.2001.280.6.E1000

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  39 in total

Review 1.  Abdominal adipose tissue distribution and metabolic risk.

Authors:  Suzy Wong; Ian Janssen; Robert Ross
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 2.  Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor gamma agonists.

Authors:  Nicholas D Oakes; Bengt Ljung; Germán Camejo
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

3.  Development and validation of a high-throughput screening assay for human long-chain fatty acid transport proteins 4 and 5.

Authors:  Wei Zhou; Peter Madrid; Amy Fluitt; Andreas Stahl; Xinmin Simon Xie
Journal:  J Biomol Screen       Date:  2010-05-06

4.  Pioglitazone increases non-esterified fatty acid clearance in upper body obesity.

Authors:  S Shadid; M D Jensen
Journal:  Diabetologia       Date:  2005-12-02       Impact factor: 10.122

5.  Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects.

Authors:  H B Holt; S H Wild; P J Wood; J Zhang; A A Darekar; K Dewbury; R B Poole; R I G Holt; D I Phillips; C D Byrne
Journal:  Diabetologia       Date:  2005-12-02       Impact factor: 10.122

6.  Very-long-chain ω-3 fatty acid supplements and adipose tissue functions: a randomized controlled trial.

Authors:  Kazanna C Hames; Maria Morgan-Bathke; Debra A Harteneck; Lendia Zhou; John D Port; Ian R Lanza; Michael D Jensen
Journal:  Am J Clin Nutr       Date:  2017-04-19       Impact factor: 7.045

7.  Errors in measuring plasma free fatty acid concentrations with a popular enzymatic colorimetric kit.

Authors:  Yilin Song; Lianzhen Zhou; Michael D Jensen
Journal:  Clin Biochem       Date:  2019-01-29       Impact factor: 3.281

8.  The effect of exercise on regional adipose tissue and splanchnic lipid metabolism in overweight type 2 diabetic subjects.

Authors:  L Simonsen; O Henriksen; L H Enevoldsen; J Bülow
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 9.  Role of body fat distribution and the metabolic complications of obesity.

Authors:  Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

10.  Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type.

Authors:  Yoshinori Miyazaki; Ralph A DeFronzo
Journal:  Cardiovasc Diabetol       Date:  2009-08-05       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.